Shares of Trulieve Cannabis Corp (OTCMKTS:TCNNF) have been assigned an average rating of “Buy” from the six brokerages that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have covered the stock in the last year is $22.31.
A number of equities analysts have weighed in on the stock. Echelon Wealth Partners reiterated a “buy” rating and issued a $23.00 price target on shares of Trulieve Cannabis in a report on Monday, May 25th. Needham & Company LLC lifted their price target on shares of Trulieve Cannabis from $18.20 to $29.25 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Trulieve Cannabis in a research note on Thursday, August 13th. Finally, Stifel Nicolaus began coverage on shares of Trulieve Cannabis in a research note on Wednesday, July 22nd. They set a “buy” rating on the stock.
Shares of OTCMKTS TCNNF opened at $20.77 on Thursday. The firm’s 50 day moving average price is $20.26 and its 200 day moving average price is $13.31. Trulieve Cannabis has a 1 year low of $5.74 and a 1 year high of $26.50.
Trulieve Cannabis Company Profile
Trulieve Cannabis Corp. operates as a medical marijuana company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as directly to patients via home delivery. It produces approximately 150 stock keeping units, including nasal sprays, capsules, concentrates, syringes, cannabis flower in tamper-proof containers for vaporizers, topical creams, tinctures, and vape cartridge.
Recommended Story: What is Liquidity?
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.